Literature DB >> 35213006

Generation of Adenovirus for In Vitro and In Vivo Studies of Hepatocytes.

Yangyang Liu1,2, Simiao Xu2,3, Yun Liu2,4, Yashaswini Kelagere Mayige Gowda5, Ji Miao6.   

Abstract

Although non-alcoholic steatohepatitis (NASH) can progress to liver cancer and liver failure, no FDA-approved drugs exist to treat NASH. Deciphering the molecular mechanisms underlying the pathogenesis of NASH will facilitate the development of effective treatments for NASH, and requires loss- or gain-of-function experimental approaches. While genetically modified animals provide important information about the function of a gene, adenovirus is a fast, effective, and versatile tool that allows transient knockdown, knockout, or overexpression of one or more genes of interest (GOIs) in primary hepatocytes in vitro and in mouse liver in vivo. In addition, adenovirus is a promising treatment method in preclinical animal models, including rodents and non-human primates, and is used in many clinical trials. Here, we describe a step-by-step protocol to generate adenovirus for basic medical research. We discuss critical steps during virus propagation and purification and provide notes about how to avoid common pitfalls.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gain- and loss-of-function; Gene transduction; Gradient centrifugation; Virial construction

Mesh:

Year:  2022        PMID: 35213006      PMCID: PMC9582736          DOI: 10.1007/978-1-0716-2128-8_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

Review 1.  Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy.

Authors:  K Jooss; N Chirmule
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

Review 2.  Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus.

Authors:  Arnold J Berk
Journal:  Oncogene       Date:  2005-11-21       Impact factor: 9.867

3.  Adenovirus protein VI mediates membrane disruption following capsid disassembly.

Authors:  Christopher M Wiethoff; Harald Wodrich; Larry Gerace; Glen R Nemerow
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  YAP suppresses gluconeogenic gene expression through PGC1α.

Authors:  Yue Hu; Dong-Ju Shin; Hui Pan; Zhiqiang Lin; Jonathan M Dreyfuss; Fernando D Camargo; Ji Miao; Sudha B Biddinger
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

5.  Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy.

Authors:  N Mittereder; K L March; B C Trapnell
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

7.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

Review 8.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

Authors:  William S M Wold; Karoly Toth
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

9.  Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine.

Authors:  Cody S Lee; Elliot S Bishop; Ruyi Zhang; Xinyi Yu; Evan M Farina; Shujuan Yan; Chen Zhao; Zongyue Zheng; Yi Shu; Xingye Wu; Jiayan Lei; Yasha Li; Wenwen Zhang; Chao Yang; Ke Wu; Ying Wu; Sherwin Ho; Aravind Athiviraham; Michael J Lee; Jennifer Moriatis Wolf; Russell R Reid; Tong-Chuan He
Journal:  Genes Dis       Date:  2017-04-27

Review 10.  Gene Therapy Leaves a Vicious Cycle.

Authors:  Reena Goswami; Gayatri Subramanian; Liliya Silayeva; Isabelle Newkirk; Deborah Doctor; Karan Chawla; Saurabh Chattopadhyay; Dhyan Chandra; Nageswararao Chilukuri; Venkaiah Betapudi
Journal:  Front Oncol       Date:  2019-04-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.